Avaí Bio, Inc. (AVAI)
| Market Cap | 19.55M -58.5% |
| Revenue (ttm) | n/a |
| Net Income | -1.81M |
| EPS | -0.01 |
| Shares Out | 153.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,600 |
| Open | 0.1290 |
| Previous Close | 0.1270 |
| Day's Range | 0.1270 - 0.1318 |
| 52-Week Range | 0.1012 - 0.8000 |
| Beta | 0.87 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Avaí Bio
Avaí Bio, Inc. acquires, creates, and develops artificial intelligence (AI) technologies. It also offers information technology (IT) consulting services. The company provides full-stack software development, database management, data integration, project management and cloud services resources. It also offers Avant! AI, a platform that has shown impressive results related to the technology’s usage, access, and performance; and InstantFAME. The company was formerly known as Avant Technologies Inc. and changed its name to Avaí Bio, Inc. in Februa... [Read more]
Financial Performance
Financial StatementsNews
Avaí Bio and Austrianova Present Encapsulated Cell Approach to Sustained α-Klotho Delivery at 2026 Klotho Conference
Avaí Bio and Austrianova presented an encapsulated-cell approach to sustained α-Klotho delivery via Klothonova at the 2026 Klotho Conference in Miami.
Avaí Bio and Austrianova Complete Adventitious Agent Testing of Master Cell Bank, Establish Working Cell Bank for α-Klotho Anti-Aging Therapy
Avaí Bio and Austrianova complete viral and adventitious agent testing of the Master Cell Bank and establish a Working Cell Bank for α-Klotho therapy.
Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes
LAS VEGAS, NEVADA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and Austrianova, its joint venture partner in Insulinova, today announced that Insulinova ha...
Avaí Bio and Austrianova Reach Agreement for Insulin-Producing Cells with Internationally Acclaimed Partner to Advance Diabetes Therapy
LAS VEGAS, July 21, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-rela...
Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy
LAS VEGAS, May 20, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-relat...
Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference
LAS VEGAS, April 7, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-rela...
Avaí Bio and Austrianova Begin Production of Master Cell Bank for Klotho Anti-Aging Therapy Under GMP Standards
LAS VEGAS, March 3, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-rela...
Avant Technologies Completes Rebranding with Name Change to Avaí Bio and Launch of New Website
LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and...
Avant Technologies Evaluating Advanced Cells for Diabetes Therapy at 15th Annual EPITA Symposium
LAS VEGAS, Jan. 26, 2026 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes an...
Avant Technologies Highlights the Critical Role of Cell Encapsulation Technology in Revolutionizing Diabetes Treatment
LAS VEGAS , Dec. 16, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes a...
Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival
LAS VEGAS , Dec. 9, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes an...
THE CRITICAL LIST: 5 Stocks Anchoring the New Economy
Issued on behalf of Quantum Security Encryption Corp. VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- USANewsGroup .com Market Intelligence Brief – The market is in triage. Speculative ...
Avant Technologies and Austrianova Secure Exclusive License for Klotho Producing Cell Line to Advance Anti-Aging Therapies
LAS VEGAS--(BUSINESS WIRE)--Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cellbased therapies for diabetes and age-related ...
Avant Technologies Signs Joint Venture to Advance Cell-Based Diabetes Treatment
LAS VEGAS--(BUSINESS WIRE)--Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), a Nevada-based corporation, and SGAustria Pte. Ltd. (SGAustria), a Singapore-based biotechnology company, ...
Avant Technologies and Austrianova Launch Klothonova, Begin Developing Age Related Cellular Therapies Using 'Longevity Protein' Klotho
LAS VEGAS , Oct. 21, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company") and global biotechnology firm, Austrianova, today announced the official launch of their join...
Avant Technologies, Inc. Bolsters Strategic Vision with Targeted Biotech Partnerships for Innovative Cell-Based Therapies
LAS VEGAS , Sept. 25, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), today announced a pivotal evolution in its business direction, emphasizing strategic partne...
Avant Technologies, Inc. Issues Retraction of September 24, 2025 Press Release
LAS VEGAS , Sept. 24, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ('Avant' or the 'Company') today announced the retraction of its press release issued on September 24, 2025, regarding...
Avant Technologies, Art-Islets, and Austrianova Announce Joint Venture to Advance Diabetes Treatment
LAS VEGAS , Sept. 24, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), a Nevada-based corporation, Art-Islets Pte.
Avant Technologies and Austrianova Sign Joint Venture, Licensing Agreement to Advance Klotho-Based Therapies
LAS VEGAS , Sept. 18, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), a Nevada-based corporation, and Austrianova (SGAustria Pte.
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
LAS VEGAS , Aug. 12, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging technology company developing healthcare solutions, and its Joint Venture partne...
Avant Technologies and Ainnova Tech Advance Clinical Trial Protocol Following FDA Feedback
LAS VEGAS , July 29, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging technology company developing healthcare solutions, and its Joint Venture partne...
Avant Technologies' Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference
LAS VEGAS , July 22, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging technology company developing healthcare solutions using both artificial intelli...
Avant Technologies and JV Partner, Ainnova, Complete Pivotal Meeting with U.S. FDA
LAS VEGAS , July 15, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company f...
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America
LAS VEGAS , July 8, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a cutting-edge healthtech company leverag...
Avant Technologies and JV Partner, Ainnova, Prepare for Key FDA Milestone with Next Week's Pre-Submission Meeting
LAS VEGAS , June 30, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company ...